We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI-Based Method Could Replace Chemical Staining of Histopathological Tissue Samples

By LabMedica International staff writers
Posted on 17 Apr 2023

For over a century, chemical staining has been a foundational technique in the study of histopathology, particularly in areas like cancer diagnostics. More...

One major drawback of chemical staining, however, is its irreversible nature, which often restricts the sample's use in other tests or experiments. To address this limitation, researchers have developed an artificial intelligence (AI)-based approach to virtually stain histopathological tissue samples, potentially replacing the need for chemical staining.

A study led by researchers from the University of Eastern Finland (Kuopio, Finland) has resulted in the development of an AI method that generates computational images closely resembling those obtained through actual chemical staining. These virtually stained images can then be examined for tissue morphology. The virtual staining technique not only reduces the chemical load and manual labor required for sample processing but also allows the tissue to be used for other purposes beyond staining. A key advantage of the proposed method is that it only requires a standard light microscope and an appropriate computer, with no need for specialized hardware or infrastructure.

The rapid advancement of deep neural networks, which learn from vast amounts of data, has revolutionized biomedical image analysis. These methods are not only suitable for traditional image analysis tasks, such as interpretation, but also excel in image-to-image transformations. Virtual staining exemplifies this type of task and was effectively demonstrated by the research team.

“The results are very widely applicable. There are plenty of topics for follow-up research, and the computational methods can still be improved. However, we can already envision several application areas where virtual staining can have a major impact in histopathology,” says Associate Professor Pekka Ruusuvuori from the University of Turku, who led the computational part of the study.

“Deep neural networks are capable of performing at a level we were not able to imagine a while ago. Artificial intelligence-based virtual staining can have a major impact towards more efficient sample processing in histopathology,” said Doctoral Researcher Umair Khan from the University of Turku who was the lead developer.

Related Links:
University of Eastern Finland 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.